EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DFMO inhibition of neuroblastoma tumorigenesis

Divya Gandra, David H Mulama, David M Foureau iD, Kimberly Q McKinney, Elizabeth Kim, Kaitlyn Smith, Jason Haw, Abhinav Nagulapally, Giselle L Saulnier Sholler iD

Cancer Medicine · 2024-05 · 13 (9)

DOI: 10.1002/cam4.7207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 30.04.2024. Verfasst von Divya Gandra und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Apoptosis, Eflornithine, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beat Childhood Cancer Foundation, Ethan's Rodeo, Meryl and Charles Witmer Foundation, Brooke's Blossoming Hope Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most high‐risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event‐free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during maintenance therapy. The effect of DFMO on cellular processes associated with neuroblastoma tumorigenesis needs further elucidation. Previous studies have shown cytotoxicity with IC50 values >5–15 mM, these doses are physiologically unattainable in patients, prompting further mechanistic studies at therapeutic doses.

Methods

We characterized the effect of DFMO on cell viability, cell cycle, apoptosis, neurosphere formation, and protein expression in vitro using five established neuroblastoma cell lines (BE2C, CHLA‐90, SHSY5Y, SMS‐KCNR, and NGP) at clinically relevant doses of 0, 50, 100, 500, 1000, and 2500 μM. Limiting Dilution studies of tumor formation in murine models were performed. Statistical analysis was done using GraphPad and the level of significance set at p = 0.05.

Results

There was not a significant loss of cell viability or gain of apoptotic activity in the in vitro assays ( p > 0.05). DFMO treatment initiated G1 to S phase cell cycle arrest. There was a dose‐dependent decrease in frequency and size of neurospheres and a dose‐dependent increase in beta‐galactosidase activity in all cell lines. Tumor formation was decreased in xenografts both with DFMO‐pretreated cells and in mice treated with DFMO.

Conclusion

DFMO treatment is cytostatic at physiologically relevant doses and inhibits tumor initiation and progression in mice. This study suggests that DFMO, inhibits neuroblastoma by targeting cellular processes integral to neuroblastoma tumorigenesis at clinically relevant doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaApoptosisEflornithineXenograft Model Antitumor AssaysCell SurvivalHumansAnimalsCell Line, TumorMiceCarcinogenesisCell CycleCell ProliferationAntineoplastic AgentsFemale

Stichwörter der Autor:innen

DFMOELDAcell cycleneuroblastomaneurospheresenescencexenograft

Substanzen

EflornithineAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA.
  • Department of Pediatrics, Levine Children's Hospital, Charlotte, North Carolina, USA.
  • Department of Medicine, Levine Cancer Institute, Charlotte, North Carolina, USA.

ORCID-Profile: David M Foureau, Giselle L Saulnier Sholler

Förderung

  • Beat Childhood Cancer Foundation
  • Ethan's Rodeo, Meryl and Charles Witmer Foundation
  • Brooke's Blossoming Hope Foundation

Zitieren

APA

Gandra, D., Mulama, D. H., Foureau, D. M., McKinney, K. Q., Kim, E., Smith, K., Haw, J., Nagulapally, A., & Saulnier Sholler, G. L. (2024). DFMO inhibition of neuroblastoma tumorigenesis. Cancer Medicine, 13(9). https://doi.org/10.1002/cam4.7207

Vancouver

Gandra D, Mulama DH, Foureau DM, McKinney KQ, Kim E, Smith K, et al. DFMO inhibition of neuroblastoma tumorigenesis. Cancer Medicine. 2024;13(9). doi:10.1002/cam4.7207

BibTeX
@article{Gandra2024,
  author = {Gandra, Divya and Mulama, David H and Foureau, David M and McKinney, Kimberly Q and Kim, Elizabeth and Smith, Kaitlyn and Haw, Jason and Nagulapally, Abhinav and Saulnier Sholler, Giselle L},
  title = {DFMO inhibition of neuroblastoma tumorigenesis},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {9},
  doi = {10.1002/cam4.7207}
}
Kostenlos starten →